Correspondence 0001213900-23-006689 from REVELATION BIOSCIENCES, INC. (REVB)
REVELATION BIOSCIENCES, INC.
Date: Feb. 1, 2023 · CIK: 0001810560 · Accession: 0001213900-23-006689
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268076
Letter
J.P. Galda & Co.
Attorneys-at-Law
40 Montgomery Avenue, LTW 220
Ardmore, Pennsylvania 19003
Telephone (215) 815-1534
February 1, 2023
Via Email and EDGAR
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attention: Daniel Crawford
Joe McCann
Re: Revelation Biosciences, Inc.
Registration Statement on Form S-1
Commission File Nos. 333-268076, 268576
Gentlemen:
Revelation Biosciences, Inc. (the “Company”) today has filed an amendment (the “Amendment”) to the above-captioned registration statements on Form S-1 as we discussed last week. The amendment updates the executive compensation disclosure, provides a business update and includes a new exchange feature for the warrants suggested by the Placement Agent. Most importantly, it reflects the authorization of additional shares of common stock to remove the exercise contingency for the offered warrants in accordance with the Staff’s oral comment.
Following discussion with Roth Capital Partners, subject to the timing of the Staff’s review, it would be the Company's plan to go effective on February 8, 2023 at the close of business, with pricing immediately thereafter, orders finalized the next day, and closing presumably on February 13, 2023. Please let us know if this is a timetable that you think you can work with.
As usual, the Company contact is Chester S, Zygmont, III, the Company's chief financial officer, whose e-mail is czygmont@revbiosciences.com. As always, thanks for your assistance.
Kind regards,
/s/ Joseph P. Galda
Show Raw Text
CORRESP 1 filename1.htm J.P. Galda & Co. Attorneys-at-Law 40 Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19003 Telephone (215) 815-1534 February 1, 2023 Via Email and EDGAR U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Daniel Crawford Joe McCann Re: Revelation Biosciences, Inc. Registration Statement on Form S-1 Commission File Nos. 333-268076, 268576 Gentlemen: Revelation Biosciences, Inc. (the “Company”) today has filed an amendment (the “Amendment”) to the above-captioned registration statements on Form S-1 as we discussed last week. The amendment updates the executive compensation disclosure, provides a business update and includes a new exchange feature for the warrants suggested by the Placement Agent. Most importantly, it reflects the authorization of additional shares of common stock to remove the exercise contingency for the offered warrants in accordance with the Staff’s oral comment. Following discussion with Roth Capital Partners, subject to the timing of the Staff’s review, it would be the Company's plan to go effective on February 8, 2023 at the close of business, with pricing immediately thereafter, orders finalized the next day, and closing presumably on February 13, 2023. Please let us know if this is a timetable that you think you can work with. As usual, the Company contact is Chester S, Zygmont, III, the Company's chief financial officer, whose e-mail is czygmont@revbiosciences.com. As always, thanks for your assistance. Kind regards, /s/ Joseph P. Galda